Respiratory Disease Testing Market By Test Type (Imaging Tests, Mechanical Tests, and In-Vitro Diagnostic Tests), By End-User (Hospitals, Diagnostic Centers, and Others) and Geography

Respiratory Disease Testing Market was valued at USD 6.782.5 million in 2023 and is expected to grow at a CAGR of 4.3% from 2024 to 2030. Respiratory testing involves various diagnostic procedures to assess lung function and identify respiratory disorders. These tests are crucial for diagnosing and monitoring conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory ailments. Respiratory diseases accounted for 7% of all global deaths in 2019, highlighting the importance of effective testing and diagnosis. The increasing prevalence of respiratory diseases, coupled with growing air pollution and smoking rates, drives the respiratory disease testing market.

Additionally, the COVID-19 pandemic has significantly heightened awareness about respiratory health, further boosting demand for testing. Technological advancements in testing equipment, such as the development of portable spirometers and AI-assisted diagnostics, contribute to market growth by improving the accessibility and accuracy of tests. Furthermore, an aging global population, more susceptible to respiratory issues, is expected to increase the demand for respiratory testing services. The market is also benefiting from increased healthcare expenditure and a growing focus on preventive care in many countries’ challenges such as the high cost of advanced testing equipment and a shortage of skilled technicians in some regions may hinder market growth. North America region held the major market share in 2023 and is expected to dominate the global Respiratory Disease Testing Market in the forecasted years.

Respiratory Disease Testing Market Key Developments:

In 2020, GE Healthcare introduced Thoracic Care Suite, a comprehensive set of eight artificial intelligence (AI) algorithms designed to

• Detect anomalies on chest X-rays
• Identify indications of pneumonia, which could potentially indicate COVID-19
• Assist radiologists by flagging issues for further assessment

In May 2022, QuantuMDx Group Limited, a UK-based company specializing in point-of-care diagnostics, launched the Q-POC™ SARS-CoV-2, Flu A/B, and RSV Assay. This development aims to:

• Expands upon their Q-POC™ SARS-CoV-2 test introduced in 2021
• Significantly enhances the capabilities of the Q-POC™ platform
• Demonstrates increased multiplex testing abilities